With new funding, Atomic AI envisions RNA as the next frontier in drug discovery
The startup is one of a handful of companies using machine learning to target RNA
Atomic AI is a startup that is using machine learning to target RNA. The company has received new funding to continue its work in this area. Atomic AI is one of a handful of companies that are using machine learning to target RNA. The others include Deep 6, Recursion Pharmaceuticals, and Insilico Medicine. These companies are all working to develop new ways to target RNA with drugs.
RNA is a key target for drug discovery because it is involved in many diseases. For example, RNA is involved in the development of cancer, Alzheimer’s disease, and Huntington’s disease. By targeting RNA, these companies hope to develop new drugs that can treat these diseases.
Atomic AI was founded in 2016 by Alex Hinrichs and Dmitrii Kiselev. The company is based in San Francisco, California. Hinrichs is a former engineer at Google. Kiselev is a former scientist at Microsoft Research. Atomic AI has raised $2.5 million in funding from In-Q-Tel, NEA, and Three Fields Capital.
The company’s technology is based on the idea that machine learning can be used to predict the structure of RNA. The company has developed a platform that can be used to design new RNA-binding drugs. The platform is called Atomnet.
Atomnet is a neural network that is trained on data from the Protein Data Bank. The Protein Data Bank is a database of proteins. Atomnet is able to learn the 3D structure of RNA from the data in the Protein Data Bank. Once Atomnet learns the 3D structure of RNA, it can be used to design new RNA-binding drugs.
Atomic AI is not the only company working on RNA-binding drugs. Deep 6 is another company that is working on this. Deep 6 is a spin-off from Google. The company was founded by Daphne Koller, a professor at Stanford University. Deep 6 has raised $10 million in funding from Google Ventures, Andreessen Horowitz, and Kleiner Perkins.
Deep 6 is using machine learning to design new drugs that target RNA. The company has developed a platform that can be used to design new RNA-binding drugs. The platform is called Deep 6. Deep 6 is a neural network that is trained on data from the Protein Data Bank. Deep 6 is able to learn the 3D structure of RNA from the data in the Protein Data Bank. Once Deep 6 learns the 3D structure of RNA, it can be used to design new RNA-binding drugs.
Deep 6 is not the only company working on RNA-binding drugs. Recursion Pharmaceuticals is another company that is working on this. Recursion Pharmaceuticals is a spin-off from the University of Utah. The company was founded by Derek Jantz and Bradley voytek. Recursion Pharmaceuticals has raised $33 million in funding from Data Collective, Formation 8, Mithril Capital Management, and Obvious Ventures.
Recursion Pharmaceuticals is using machine learning to design new drugs that target RNA. The company has developed a platform that can be used to design new RNA-binding drugs. The platform is called Recursion. Recursion is a neural network that is trained on data from the Protein Data Bank. Recursion is able to learn the 3D structure of RNA from the data in the Protein Data Bank. Once Recursion learns the 3D structure of RNA, it can be used to design new RNA-binding drugs.
Insilico Medicine is another company that is working on RNA-binding drugs. Insilico Medicine is a spin-off from Johns Hopkins University. The company was founded by Alex Zhavoronkov. Insilico Medicine has raised $4.5 million in funding from Google, Pfizer, and BBVA.
Insilico Medicine is using machine learning to design new drugs that target RNA. The company has developed a platform that can be used to design new RNA-binding drugs. The platform is called In silico. In silico is a neural network that is trained on data from the Protein Data Bank. In silico is able to learn the 3D structure of RNA from the data in the Protein Data Bank. Once In silico learns the 3D structure of RNA, it can be used to design new RNA-binding drugs.
Atomic AI is one of a handful of companies that are using machine learning to target RNA. The company has received new funding to continue its work in this area. Atomic AI is one of a handful of companies that are using machine learning to target RNA. The others include Deep 6, Recursion Pharmaceuticals, and Insilico Medicine. These companies are all working to develop new ways to target RNA with drugs.